{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:48:40Z","timestamp":1781290120176,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clgc.2022.01.017","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T20:34:52Z","timestamp":1643747692000},"page":"260-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1305-5399","authenticated-orcid":false,"given":"Jianyi","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8555-4322","authenticated-orcid":false,"given":"Roy","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-149X","authenticated-orcid":false,"given":"Nicholas","family":"Levonyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-6349","authenticated-orcid":false,"given":"Annapoorani","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-1174","authenticated-orcid":false,"given":"Nisa","family":"Kubiliun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.01.017_bib0001","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.01.017_bib0002","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.01.017_bib0003","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.01.017_bib0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41585-020-0282-3","article-title":"Checkpoint inhibitor immunotherapy in kidney cancer","volume":"17","author":"Xu","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0005","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0006","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.clgc.2022.01.017_bib0007","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA Clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clgc.2022.01.017_bib0008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CJI.0000000000000213","article-title":"The Risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"41","author":"Tandon","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.clgc.2022.01.017_bib0009","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0010","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2022.01.017_bib0012","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0013","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2022.01.017_bib0014","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.clgc.2022.01.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clgc.2022.01.017_bib0016","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2022.01.017_bib0017","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1073\/pnas.1712901115","article-title":"Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade","volume":"115","author":"Wang","year":"2018","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.clgc.2022.01.017_bib0018","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2022.01.017_bib0019","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10620-020-06103-x","article-title":"Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis","volume":"65","author":"Abu-Sbeih","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clgc.2022.01.017_bib0020","first-page":"1368","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of oncology : official journal of the European Society for","volume":"28","author":"Chaput","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0021","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/s41467-018-05184-7","article-title":"Gut microbiota associations with common diseases and prescription medications in a population-based cohort","volume":"9","author":"Jackson","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2022.01.017_bib0022","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/apt.14451","article-title":"Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications","volume":"47","author":"Le Bastard","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clgc.2022.01.017_bib0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1756283X12437358","article-title":"Overutilization of proton-pump inhibitors: what the clinician needs to know","volume":"5","author":"Heidelbaugh","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0024","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/apt.14916","article-title":"Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study","volume":"48","author":"Bonderup","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clgc.2022.01.017_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1060028016673859","article-title":"Association Between Proton Pump Inhibitors and Microscopic Colitis","volume":"51","author":"Law","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clgc.2022.01.017_bib0026","first-page":"489","article-title":"Proton pump inhibitors, H2 blocker use, and risk of inflammatory bowel disease in children","volume":"24","author":"Schwartz","year":"2019","journal-title":"J Pediatr Pharmacol Therap"},{"key":"10.1016\/j.clgc.2022.01.017_bib0027","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2036.2012.05173.x","article-title":"Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease","volume":"36","author":"Juillerat","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clgc.2022.01.017_bib0028","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000455008","article-title":"Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease","volume":"95","author":"Shah","year":"2017","journal-title":"Digestion"},{"key":"10.1016\/j.clgc.2022.01.017_bib0029","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ibd\/izy240","article-title":"Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?","volume":"25","author":"Choi","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clgc.2022.01.017_bib0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOG.0000000000000482","article-title":"Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?","volume":"34","author":"Siakavellas","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0031","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clgc.2022.01.017_bib0032","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0033","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the american gastroenterological association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clgc.2022.01.017_bib0034","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","article-title":"Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis","volume":"14","author":"Verschuren","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0035","first-page":"1","article-title":"Association of chronic immune-mediated diarrhea and colitis with favorable cancer response","author":"Zou","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2022.01.017_bib0036","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/apt.13583","article-title":"High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors","volume":"43","author":"Verhaegh","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clgc.2022.01.017_bib0037","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0038","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.clgc.2022.01.017_bib0039","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.clgc.2022.01.017_bib0040","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","article-title":"Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified","volume":"25","author":"Bruno","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0041","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/cncr.32966","article-title":"Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis","volume":"126","author":"Grover","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.01.017_bib0042","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/codi.14114","article-title":"Decreased risk for microscopic colitis and inflammatory bowel disease among patients with reflux disease","volume":"20","author":"Sonnenberg","year":"2018","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.clgc.2022.01.017_bib0043","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","article-title":"Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis","volume":"23","author":"Trifan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clgc.2022.01.017_bib0044","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mayocp.2017.10.022","article-title":"Proton pump inhibitors: review of emerging concerns","volume":"93","author":"Nehra","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clgc.2022.01.017_bib0045","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/1759-7714.13470","article-title":"Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer","volume":"11","author":"Diao","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clgc.2022.01.017_bib0046","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.01.017_bib0047","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929727","article-title":"Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer","volume":"10","author":"Qin","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clgc.2022.01.017_bib0048","first-page":"354","article-title":"Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Physician"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:12Z","timestamp":1761564972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1558767322000350"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.01.017","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}